ME02119B - Spojevi korisni za inhibiranje chk1 - Google Patents
Spojevi korisni za inhibiranje chk1Info
- Publication number
- ME02119B ME02119B MEP-2015-69A MEP6915A ME02119B ME 02119 B ME02119 B ME 02119B ME P6915 A MEP6915 A ME P6915A ME 02119 B ME02119 B ME 02119B
- Authority
- ME
- Montenegro
- Prior art keywords
- cancer
- salt
- compound
- methylpyridin
- pyrazin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 14
- 101150050673 CHK1 gene Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 12
- LAEFIEWPUJMANC-CYBMUJFWSA-N n-[5-(2-methoxy-6-methylpyridin-3-yl)-1h-pyrazol-3-yl]-6-[(3r)-piperidin-3-yl]oxypyrazin-2-amine Chemical compound COC1=NC(C)=CC=C1C1=NNC(NC=2N=C(O[C@H]3CNCCC3)C=NC=2)=C1 LAEFIEWPUJMANC-CYBMUJFWSA-N 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 230000005865 ionizing radiation Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960005079 pemetrexed Drugs 0.000 claims 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/06—Oxalic acid
- C07C55/07—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (13)
1.Spoj, naznačen time što je (R)-[5-(2-metoksi-6-metilpiridin-3-il)-2H-pirazol-3-il][6-(piperidin-3-iloksi)pirazin-2-il]amin, ili njegova farmaceutski prihvatljiva sol.
2.Spoj u skladu s patentnim zahtjevom 1, naznačen time što je (R)-[5-(2-metoksi-6-metilpiridin-3-il)-2H-pirazol-3-il][6-(piperidin-3-iloksi)pirazin-2-il]amin.
3.Spoj u skladu s patentnim zahtjevom 1, naznačen time što je sol (R)-[5-(2-metoksi-6-metilpiridin-3-il)-2H-pirazol-3-il][6-(piperidin-3-iloksi)pirazin-2-il]amina s metansulfonskom kiselinom.
4.Spoj u skladu s patentnim zahtjevom 1, naznačen time što je sol (R)-[5-(2-metoksi-6-metilpiridin-3-il)-2H-pirazol-3-il][6-(piperidin-3-iloksi)pirazin-2-il]amina s octenom kiselinom.
5.Spoj u skladu s patentnim zahtjevom 1, naznačen time što je hemioksalatna sol (R)-[5-(2-metoksi-6-metilpiridin-3-il)-2H-pirazol-3-il][6-(piperidin-3-iloksi)pirazin-2-il]amina.
6.Spoj u skladu s patentnim zahtjevom 1, naznačen time što je hemisukcinatna sol (R)-[5-(2-metoksi-6-metilpiridin-3-il)-2H-pirazol-3-il][6-(piperidin-3-iloksi)pirazin-2-il]amina.
7.Farmaceutski pripravak, naznačen time što sadrži spoj ili sol u skladu bilo kojim od patentnih zahtjeva 1-6, kao i farmaceutski prihvatljivu podlogu, razrjeđivač ili pomoćnu tvar.
8.Spoj ili sol u skladu bilo kojim od patentnih zahtjeva 1-6, naznačeni time što su namijenjeni upotrebi u terapiji.
9.Spoj ili sol u skladu bilo kojim od patentnih zahtjeva 1-6, naznačeni time što su namijenjeni upotrebi u liječenju raka.
10.Spoj ili sol u skladu bilo kojim od patentnih zahtjeva 1-6, naznačeni time što su namijenjeni upotrebi u istodobnoj, odvojenoj ili uzastopnoj kombinaciji s ionizirajućim zračenjem u liječenju raka.
11.Spoj ili sol u skladu bilo kojim od patentnih zahtjeva 1-6, naznačeni time što su namijenjeni upotrebi u istodobnoj, odvojenoj ili uzastopnoj kombinaciji s jednim ili više kemoterapijskih sredstava u liječenju raka.
12.Spoj ili sol namijenjeni upotrebi u skladu s patentnim zahtjevom 11, naznačeni time što se jedno ili više kemoterapijskih sredstava bira iz skupine koju čine 5-fluoruracil, hidroksiurea, gemcitabin, metotreksat, pemetreksed, doksorubicin, etopozid, cisplatin i taksol.
13.Spoj ili sol namijenjeni upotrebi u skladu bilo kojim od patentnih zahtjeva 9-12, naznačeni time što se rak bira iz skupine koju čine rak mokraćnog mjehura, rak debelog crijeva, rak želuca, rak jetre, rak pluća, rak dojke, melanom, rak jajnika, rak gušterače, mezoteliom, rak bubrega i rak maternice.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41113710P | 2010-11-08 | 2010-11-08 | |
| PCT/US2011/058692 WO2012064548A1 (en) | 2010-11-08 | 2011-11-01 | Compounds useful for inhibiting chk1 |
| EP11788263.9A EP2638033B1 (en) | 2010-11-08 | 2011-11-01 | Compounds useful for inhibiting chk1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02119B true ME02119B (me) | 2015-10-20 |
Family
ID=45044707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-69A ME02119B (me) | 2010-11-08 | 2011-11-01 | Spojevi korisni za inhibiranje chk1 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9067920B2 (me) |
| EP (1) | EP2638033B1 (me) |
| JP (1) | JP5792316B2 (me) |
| KR (1) | KR101533166B1 (me) |
| CN (1) | CN103180311B (me) |
| AR (1) | AR083575A1 (me) |
| AU (1) | AU2011326230B2 (me) |
| BR (1) | BR112013010009B1 (me) |
| CA (1) | CA2816944C (me) |
| DK (1) | DK2638033T3 (me) |
| EA (1) | EA022096B1 (me) |
| ES (1) | ES2541414T3 (me) |
| HR (1) | HRP20150530T1 (me) |
| JO (1) | JO3145B1 (me) |
| ME (1) | ME02119B (me) |
| MX (1) | MX2013005181A (me) |
| PL (1) | PL2638033T3 (me) |
| PT (1) | PT2638033E (me) |
| RS (1) | RS54012B1 (me) |
| SI (1) | SI2638033T1 (me) |
| TW (1) | TWI501956B (me) |
| WO (1) | WO2012064548A1 (me) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201402277D0 (en) | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CN108601781B (zh) | 2016-02-04 | 2019-11-22 | 广州必贝特医药技术有限公司 | 作为检测点激酶1(chk1)抑制剂的3,5-二取代吡唑及其制备及应用 |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| CN112457306A (zh) | 2019-09-06 | 2021-03-09 | 上海瑛派药业有限公司 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
| CA3200498A1 (en) | 2020-11-30 | 2022-06-02 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1h-pyrazol-3-amine derivative |
| US11564920B2 (en) | 2020-11-30 | 2023-01-31 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1H-pyrazol-3-amine derivative |
| UY39832A (es) | 2021-06-28 | 2023-01-31 | Blueprint Medicines Corp | Inhibidores de cdk2 |
| TW202333680A (zh) | 2021-12-24 | 2023-09-01 | 日商住友製藥股份有限公司 | 具有二環性骨架之1h-吡唑-3-胺衍生物 |
| EP4534100A1 (en) * | 2022-05-27 | 2025-04-09 | Sumitomo Pharma Co., Ltd. | Therapeutic for cancer refractory to immune checkpoint inhibitor |
| CN121311482A (zh) * | 2023-04-14 | 2026-01-09 | 缆图药品公司 | Cdk2抑制剂 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006528661A (ja) * | 2003-07-25 | 2006-12-21 | ファイザー・インク | アミノピラゾール化合物およびｃｈｋ１阻害剤としての使用 |
| DE602004031777D1 (en) * | 2004-01-05 | 2011-04-21 | Astrazeneca Ab | Thiophenderivate als chk-1-inhibitoren |
| WO2005121121A2 (en) | 2004-06-04 | 2005-12-22 | Arena Pharmaceuticals, Inc. | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| WO2006117560A1 (en) * | 2005-05-05 | 2006-11-09 | Astrazeneca Ab | Pyrazolyl-amino- substituted pyrimidines and their use in the treatment of cancer |
| CA2610884A1 (en) * | 2005-06-09 | 2006-12-21 | Merck & Co., Inc. | Inhibitors of checkpoint kinases |
| WO2008117050A1 (en) * | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
| PA8850801A1 (es) * | 2008-12-17 | 2010-07-27 | Lilly Co Eli | Compuestos útiles para inhibir chk1 |
-
2011
- 2011-10-27 JO JOP/2011/0323A patent/JO3145B1/ar active
- 2011-10-27 AR ARP110103973A patent/AR083575A1/es active IP Right Grant
- 2011-10-28 TW TW100139492A patent/TWI501956B/zh active
- 2011-11-01 DK DK11788263T patent/DK2638033T3/en active
- 2011-11-01 MX MX2013005181A patent/MX2013005181A/es active IP Right Grant
- 2011-11-01 WO PCT/US2011/058692 patent/WO2012064548A1/en not_active Ceased
- 2011-11-01 EA EA201390499A patent/EA022096B1/ru not_active IP Right Cessation
- 2011-11-01 ES ES11788263.9T patent/ES2541414T3/es active Active
- 2011-11-01 ME MEP-2015-69A patent/ME02119B/me unknown
- 2011-11-01 BR BR112013010009-5A patent/BR112013010009B1/pt active IP Right Grant
- 2011-11-01 US US13/877,923 patent/US9067920B2/en active Active
- 2011-11-01 PL PL11788263T patent/PL2638033T3/pl unknown
- 2011-11-01 AU AU2011326230A patent/AU2011326230B2/en active Active
- 2011-11-01 JP JP2013537756A patent/JP5792316B2/ja active Active
- 2011-11-01 KR KR1020137011808A patent/KR101533166B1/ko active Active
- 2011-11-01 RS RS20150352A patent/RS54012B1/sr unknown
- 2011-11-01 SI SI201130467T patent/SI2638033T1/sl unknown
- 2011-11-01 PT PT117882639T patent/PT2638033E/pt unknown
- 2011-11-01 CA CA2816944A patent/CA2816944C/en active Active
- 2011-11-01 CN CN201180053779.8A patent/CN103180311B/zh active Active
- 2011-11-01 EP EP11788263.9A patent/EP2638033B1/en active Active
- 2011-11-01 HR HRP20150530TT patent/HRP20150530T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA022096B1 (ru) | 2015-10-30 |
| KR101533166B1 (ko) | 2015-07-01 |
| BR112013010009B1 (pt) | 2021-10-19 |
| HRP20150530T1 (hr) | 2015-06-19 |
| TWI501956B (zh) | 2015-10-01 |
| EP2638033B1 (en) | 2015-04-08 |
| PT2638033E (pt) | 2015-06-01 |
| AR083575A1 (es) | 2013-03-06 |
| MX2013005181A (es) | 2013-10-17 |
| RS54012B1 (sr) | 2015-10-30 |
| CA2816944A1 (en) | 2012-05-18 |
| SI2638033T1 (sl) | 2015-05-29 |
| AU2011326230A1 (en) | 2013-05-09 |
| CN103180311A (zh) | 2013-06-26 |
| CN103180311B (zh) | 2014-08-20 |
| DK2638033T3 (en) | 2015-04-27 |
| ES2541414T3 (es) | 2015-07-20 |
| AU2011326230B2 (en) | 2015-02-19 |
| JO3145B1 (ar) | 2017-09-20 |
| US9067920B2 (en) | 2015-06-30 |
| KR20130099146A (ko) | 2013-09-05 |
| EA201390499A1 (ru) | 2013-08-30 |
| WO2012064548A1 (en) | 2012-05-18 |
| EP2638033A1 (en) | 2013-09-18 |
| JP5792316B2 (ja) | 2015-10-07 |
| PL2638033T3 (pl) | 2015-09-30 |
| TW201305138A (zh) | 2013-02-01 |
| JP2013541586A (ja) | 2013-11-14 |
| CA2816944C (en) | 2015-12-22 |
| US20130190262A1 (en) | 2013-07-25 |
| BR112013010009A2 (pt) | 2020-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02119B (me) | Spojevi korisni za inhibiranje chk1 | |
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| HRP20130167T1 (hr) | Spojevi korisni za inhibiranje chk1 | |
| JP2013541586A5 (me) | ||
| ME02663B (me) | Derivati benzimidazola kao inhibitori pi3 kinaze | |
| NZ630205A (en) | Enhancer of zeste homolog 2 inhibitors | |
| MX2015012432A (es) | Inhibidores piridinicos de la cinasa cdk9. | |
| PH12015502628B1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| MX2014012741A (es) | Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor 4 activado de proteasa (par4) para tratamiento de agregacion plaquetaria. | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| BR112012027743A2 (pt) | ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas | |
| UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
| MX2014012454A (es) | Derivados de imidazotiadiazol como inhibidores del receptor 4 activado de proteasa (par4) para el tratamiento de agregacion plaquetaria. | |
| TN2017000511A1 (en) | New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them. | |
| MX2010003868A (es) | Cis-imidazolinas quirales. | |
| WO2015132799A3 (en) | Heterocyclic compounds | |
| MY180618A (en) | Pyridazinone compounds and their use as daao inhibitors | |
| MX2009008953A (es) | Compuestos como inhibidores de angiogenesis. | |
| MX2009009843A (es) | Compuestos espiro sustituidos como inhibidores de la angiogenesis. | |
| WO2009007390A3 (en) | 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| SV2016005351A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| WO2013040227A3 (en) | Therapeutic compounds | |
| WO2012168885A9 (en) | Bisacodyl and its analogues as drugs for use in the treatment of cancer | |
| HRP20120762T1 (hr) | Tetrasupstituirani piridazini kao inhibitori hedgehog puta |